rhIL-11 for the prevention of dose-limiting chemotherapy-induced thrombocytopenia.
Kurzrock
R
R
Section of Cytokines, University of Texas, M. D. Anderson Cancer Center, Houston, USA.
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D001792:Blood Platelets / Q000187:drug effects; D003115:Colony-Stimulating Factors / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D006410:Hematopoiesis / Q000187:drug effects*; D006801:Humans; D017370:Interleukin-11 / Q000627:therapeutic use*; D020714:Maximum Tolerated Dose; D008533:Megakaryocytes / Q000187:drug effects; D011994:Recombinant Proteins / Q000627:therapeutic use*; D013921:Thrombocytopenia / Q000139:chemically induced / Q000517:prevention & control*
D000970:Antineoplastic Agents; D003115:Colony-Stimulating Factors; D017370:Interleukin-11; D011994:Recombinant Proteins; C105308:oprelvekin